Proleukin aldesleukin

Drug Class

Recombinant human interleukin-2

Mechanism

Acts as an immunological modifier that stimulates T-cell and natural killer (NK) cell activation and proliferation, promoting host immune defense against tumor cells.

Approved Indication

Metastatic renal cell carcinoma and metastatic melanoma, per its FDA approval.

What This Means For Patients

Proleukin is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (1992) — Sources

Pivotal Clinical Evidence

• Aldesleukin RCC Study Group — Fyfe et al., J Clin Oncol 1995 — Sources

Sources

• https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103293
• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1129532/